Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by JLGeminion Mar 24, 2011 10:00pm
147 Views
Post# 18338106

RE: RE: Change of Focus in the Board Discussion

RE: RE: Change of Focus in the Board Discussion

Hey, lightweight  (OrdinaryAverageGuy1) read your post again.  Your boss will not be impressed by it.  I picture you as the new MBA who has joined an investment bank which has a vested interest in pleasing their institutional clients.  You did well in your MBA to land the job with the expected yellow brick road to riches.  I bet you got an A+ in your ethics course.  Too bad, you do not have any.  You also may not last in your position.

 

As for one of your first assignments, you are not doing well posting on this Board.  Your first mistake was using the investment bank’s system so the Stockhouse’s system recognized you as a pro and granted a starting reputation rating of 1.  You are a cocky SOB and used the firms’ insider information to increase the rating to 2 by adding a performance rating of 1. Since Feb 24, you have made 35 posts with a total number of hits of 5,142.  Averaging under 150 hits per post hardly justifies a reputation rating of 2, particularly when they are all personal attacks against me.  I’m flattered that your boss is so concerned about my message to retail investors to buy and hold that he assigned you to the case.  You are not getting the job done.

 

Thank you for your concerns about my health.  I do not find the status of my health material to a discussion board on investments.  If you must know, I’m the picture of good health.  The point regarding dying of cancer is that Reolysin will not be a discretionary purchase.  The state of the global economy and international events will have negligible impact on Reolysin’s sales volumes.  Do you think Michael Douglas’ wealth and name got him access to a Reolysin trial?  What straw is Steve Jobs reaching for?  Cancer is a cruel disease that can attack anyone.

 

As for my personal finances and margin calls, they are none of your business.  I will leave you with a quiz and a question.  ONC opened 2010 at $2.75 and closed the year at $6.73.  If I had owned 10,000 shares, I would have made $39,800.  The quiz is how many shares did I own last year and how much did I make.  Was it under $50,000, $50,000 - $100,000, $100,000 – 250,000, $250,000 - $500,000, $500,000 - $1,000,000, or over $1,000,000?  The question is that Oncolytics having the potential to pass $25 a share, why should I hold mutual funds over ONC?

Bullboard Posts